Maynard Um
-
-
-
-
-
-
-
Coya Therapeutics study shows immune dysfunction in dementia patients
-
-
-
-
-
-
-
Coya Therapeutics receives Health Canada approval for ALS trial expansion
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)
-
-
-
-
-
-
-
Coya Therapeutics, Inc. (COYA) Misses Q2 EPS by 49c
-
-
-
-
-
-
-
Coya Therapeutics, Inc. (COYA) Tops Q1 EPS by 2c
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Support
-
-
-
-
-
-
-
Coya Therapeutics (COYA) Reports Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2
-
447,987 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

